SCHEMBL5138032

SCHEMBL5138032

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
MMP13 P45452 1/20 0.40
TRPM8 Q7Z2W7 2/20 0.40
TSHR P16473 2/20 0.39
CRHR1 P34998 4/20 0.39
DHFR P00374 2/20 0.39
CNR2 P34972 1/20 0.37
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
SERPINE1 P05121 1/20 0.36
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
CACNA2D1 P54289 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136840 0.95 C5AR1 (0.41) C5AR1MMP13TRPM8TSHRCRHR1
SCHEMBL5137638 0.94 C5AR1 (0.41) C5AR1MMP13TRPM8TSHRCRHR1
SCHEMBL5136018 0.94 C5AR1 (0.41) C5AR1MMP13TRPM8TSHRCRHR1
SCHEMBL5136208 0.94 CRHR1 (0.43) C5AR1TRPM8TSHRCRHR1DHFR
SCHEMBL648971 0.93 C5AR1 (0.42) C5AR1MMP13TRPM8CRHR1DHFR
SCHEMBL651505 0.93 C5AR1 (0.40) C5AR1MMP13TRPM8TSHRCRHR1
SCHEMBL5136025 0.92 TRPM8 (0.45) TRPM8
SCHEMBL5134680 0.92 C5AR1 (0.43) C5AR1TSHRCRHR1PTGDR2
SCHEMBL5135486 0.91 C5AR1 (0.42) C5AR1MMP13CRHR1PPARGPPARA
SCHEMBL1912982 0.91 TRPM8 (0.44) C5AR1TRPM8CNR2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed